Home > Insider Trading > Filing (0000899243-20-020215)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1807901	Pandion Therapeutics Inc.	PAND	Pharmaceutical Preparations (2834)	833015614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1817591	Mitchell Mutz	C/O Pandion Therapeutics, Inc., 134 Coolidge Avenue Watertown MA 02472		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-07-21	3,049,973	$0.00	3,049,973	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2020-07-21	36,111	$18.00	3,086,084	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2020-07-21	10,000	$18.00	10,000	No	4	P	Indirect	By wife

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote
No	4	P	Indirect	By wife

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Preferred Stock	Disposition	2020-07-21	13,138,905	$0.00	2,576,564	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-07-21	2,414,098	$0.00	473,409	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Roche Finance Ltd ("Roche Finance") is the direct beneficial owner of these securities of the Issuer. Roche Finance is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer.
Represents shares purchased by Mr. Mutz's wife through a directed share program in connection with the initial public offering of Pandion Therapeutics, Inc.'s common stock, which closed on July 21, 2020. These shares of common stock were purchased at the public offering price of $18.00 per share.